CHRONIC NEUTROPHILIC LEUKEMIA
Clinical trials for CHRONIC NEUTROPHILIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC NEUTROPHILIC LEUKEMIA trials appear
Sign up with your email to follow new studies for CHRONIC NEUTROPHILIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood cancers: drug trial aims to shrink spleens and ease suffering
Disease control OngoingThis study is testing if the drug fedratinib is effective and safe for people with rare, hard-to-treat blood cancers. It will involve about 25 adults with specific conditions like MDS/MPN or chronic neutrophilic leukemia. The main goal is to see if the drug can control the diseas…
Matched conditions: CHRONIC NEUTROPHILIC LEUKEMIA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New Triple-Threat treatment tested for aggressive blood cancers
Disease control OngoingThis study is testing a combination of three drugs—azacitidine, venetoclax, and pevonedistat—for adults newly diagnosed with certain high-risk blood cancers. These include acute myeloid leukemia (AML) that developed from other blood disorders or prior cancer treatment, as well as…
Matched conditions: CHRONIC NEUTROPHILIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New strategy aims to tame dangerous virus after cancer transplant
Disease control OngoingThis study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…
Matched conditions: CHRONIC NEUTROPHILIC LEUKEMIA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC